PMC:7534795 / 22698-23063 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T120","span":{"begin":311,"end":315},"obj":"Body_part"}],"attributes":[{"id":"A120","pred":"fma_id","subj":"T120","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":" years of age with severe infection\n• Primary outcome of time to clinical improvement\n• N = 20 ruxolitinib + standard care\n• N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily\n• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)\n• Improvement in lung computerized tomography (CT) scans\n• Significantl"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T42","span":{"begin":311,"end":315},"obj":"Body_part"}],"attributes":[{"id":"A42","pred":"uberon_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":" years of age with severe infection\n• Primary outcome of time to clinical improvement\n• N = 20 ruxolitinib + standard care\n• N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily\n• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)\n• Improvement in lung computerized tomography (CT) scans\n• Significantl"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T186","span":{"begin":26,"end":35},"obj":"Disease"}],"attributes":[{"id":"A186","pred":"mondo_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":" years of age with severe infection\n• Primary outcome of time to clinical improvement\n• N = 20 ruxolitinib + standard care\n• N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily\n• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)\n• Improvement in lung computerized tomography (CT) scans\n• Significantl"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T61281","span":{"begin":311,"end":315},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T18574","span":{"begin":311,"end":315},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":" years of age with severe infection\n• Primary outcome of time to clinical improvement\n• N = 20 ruxolitinib + standard care\n• N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily\n• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)\n• Improvement in lung computerized tomography (CT) scans\n• Significantl"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T165","span":{"begin":96,"end":107},"obj":"Chemical"},{"id":"T166","span":{"begin":199,"end":208},"obj":"Chemical"},{"id":"T167","span":{"begin":199,"end":206},"obj":"Chemical"}],"attributes":[{"id":"A165","pred":"chebi_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/CHEBI_66919"},{"id":"A166","pred":"chebi_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/CHEBI_21241"},{"id":"A167","pred":"chebi_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/CHEBI_33229"}],"text":" years of age with severe infection\n• Primary outcome of time to clinical improvement\n• N = 20 ruxolitinib + standard care\n• N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily\n• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)\n• Improvement in lung computerized tomography (CT) scans\n• Significantl"}

{"project":"LitCovid-sentences","denotations":[{"id":"T159","span":{"begin":36,"end":85},"obj":"Sentence"},{"id":"T160","span":{"begin":86,"end":123},"obj":"Sentence"},{"id":"T161","span":{"begin":124,"end":188},"obj":"Sentence"},{"id":"T162","span":{"begin":189,"end":293},"obj":"Sentence"},{"id":"T163","span":{"begin":294,"end":350},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" years of age with severe infection\n• Primary outcome of time to clinical improvement\n• N = 20 ruxolitinib + standard care\n• N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily\n• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)\n• Improvement in lung computerized tomography (CT) scans\n• Significantl"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T93","span":{"begin":19,"end":35},"obj":"Phenotype"}],"attributes":[{"id":"A93","pred":"hp_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/HP_0032169"}],"text":" years of age with severe infection\n• Primary outcome of time to clinical improvement\n• N = 20 ruxolitinib + standard care\n• N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily\n• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)\n• Improvement in lung computerized tomography (CT) scans\n• Significantl"}